思凌创展取得一项电子医疗保健技术专利权

by Yijing 0 comments

News

2015年10月7日 中国北京 法国巴黎 —— 思凌创展作为帮助客户在医疗保健领域实现商业化的前端服务伙伴,宣布在中国和印度取得了一项非介入筛查体内重金属含量技术的专利权。这项技术由一个分光光度仪和软件即服务(SaaS)模式构成。它具备检测体内重金属和微量元素含量的功能,并将在以Oligoscan® 欧立健™品牌投入中国市场。该产品为欧洲制造,且已经取得了CE认证标志和ISO13485标准。 思凌创展总经理Gaëtan de KERROS补充道:

       “在中国和印度,近期的政府举措、传统媒体和社交媒体的传播都大幅度提升了公众对于环境污染的重视程度。这项非介入的、采用联网模式的技术有助于筛查大量人口体内重金属和微量元素含量。它通过提供一份综合全面的报告,为达到营养平衡和拥有健康的生活方式提供参考。

 

SPIREN Ventures acquires the Exclusive Rights of a Digital Health technology, screening Heavy Metals, in China and India.

by Spiren 1 comments

News

d39e1b17-67c5-44f5-b7a2-f5417183076aBeijing (China), Paris (France), October 7, 2015 – SPIREN Ventures, a Commercialization Front Office, specialized in HealthCare, announces the acquisition of the Exclusive Rights of a non-invasive technology screening Heavy Metals, in China and India. This technology is comprised of a medical device and a Service as a Software (SaaS) model. It screens heavy metals and mineral deficiencies, and will be marketed in China under the brand Oligoscan® 欧立健™. Made in Europe, it has been granted CE mark, and ISO 13485 certificate. Gaëtan de KERROS, Managing Director of SPIREN Ventures, adds up: “recent government initiatives, traditional and social medias have raised exceptional awareness around pollution particularly in China and India. This non-invasive and connected technology helps screen Heavy Metals as well as Mineral Deficiencies among a large population. It provides a comprehensive report which contributes to achieve a balanced nutrition and healthy life style”.  

A New Partnership in M & A in China

by Spiren 0 comments

News

06-2-940x587 Beijing (China), Paris (France), September 30, 2015 – SPIREN HealthCare, a strategy consulting firm specialized in Life Science industries and TONGTAI Uni-trust HealthCare Investing Co. Ltd, a Mergers & Acquisitions firm, announce a partnership today. This aims at partnering with CEO’s of Life Science companies looking for Mergers & Acquisitions and fund raising in China. This Partnership is grounded in a rare combination of healthcare Expertise, Experience track records and exceptional Network in China with Strategic and Financial Investors.    

Guerbet signs agreement with Kyuan in China

by Spiren 0 comments

News

IMG_0636 Pleased to share the news! Guerbet (GBT) announced today the signing of an agreement with Beijing Kyuan Pharmaceutical Co., Ltd., one of the major pharmaceutical drugs distributors & importers in the Chinese market, to distribute & commercialize Lipiodol® Ultra-Fluid as from September 2015. Founded in 1995, Kyuan is part of the Shanghai Pharma group (SPH) - China’s second biggest pharmaceutical distribution group - since 2011. This agreement enables Guerbet flagship Interventional Radiology agent to benefit from Kyuan’s outstanding experience in distributing pharmaceuticals on the hospital market.